Aliskiren Evaluation on Left Ventricular Diastolic Dysfunction

Aliskiren Evaluation on Left Ventricular Diastolic Dysfunction - ALEDY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005796

Enrollment

Registered

2011-06-20

Start date

2011-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction and hypertension

Interventions

Aliskiren group and Standard therapy group test period 24weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age; 20-80 years old Bp>140/90mmHg LVEF>45% Diastlic dysfunction by Doppler echocardiography

Exclusion criteria

Exclusion criteria: secondary HT, Diabetes Mellitus, significant systolic dysfunction, serum creatinine>2mg/dl, significant liver dysfunction, acute phase of myocardial infarction or cerebrovascular disease atrial fibrillation

Design outcomes

Primary

Measure	Time frame
LV diastolic function, biomarker of myocardial fibrillation and systemic inflammation, coronary flow velocity reserve	—

Countries

Japan

Contacts

Public ContactHiromi Shinoki

Clinical Trials Support Office Clinical Trials Support Office

tiken@shi.heart.or.jp042-314-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026